Indication

Lipodystrophy associated with human immunodeficiency virus infection

Lipodystrophy associated with human immunodeficiency virus infection is an acquired disorder of adipose tissue distribution and metabolism occurring in individuals living with HIV, most frequently linked to antiretroviral therapy regimens. Read more about Lipodystrophy associated with human immunodeficiency virus infection

3 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Lipodystrophy associated with human immunodeficiency virus infection therapies.

Showing 1–3 of 3 drugs

Filter & compare in the drug finder →Opens the drug finder with Lipodystrophy associated with human immunodeficiency virus infection preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Lipodystrophy associated with human immunodeficiency virus infection.

Lipodystrophy associated with human immunodeficiency virus infection is an acquired disorder of adipose tissue distribution and metabolism occurring in individuals living with HIV, most frequently linked to antiretroviral therapy regimens.

It primarily affects the adipose, metabolic, and cardiovascular systems and presents as lipoatrophy, lipohypertrophy, or a mixed phenotype.

Defining clinical features include the loss of peripheral subcutaneous adipose tissue in the face, limbs, and buttocks, abnormal visceral and truncal fat deposition in the abdomen, breasts, or dorsocervical region, and concurrent metabolic disruptions such as severe insulin resistance and dyslipidemia.

Personalize your experience

Follow Lipodystrophy associated with human immunodeficiency virus infection and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it